Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
Entecavir
